

LENTISTABLE™


High-titre packaging and producer cell lines



Why choose Oxford Biomedica for your stable producer cell line development?

LentiStable™

Our expert team can design and generate your producer cell line (PCL) in less than 8 months



Accelerated development timelines

- Automated stable cell line development enables the screening of over a thousand clones in a shorter timeframe
- Core cell line development phase delivers high-titre PCLs in 6 months

Experience

More than 25 years experience including 15 years developing stable cell lines

Innovation

Unique technologies enabling the development of any producer cell line

Performance

Access relevant data on cell line performance in a scalable perfusion process

Success


Producer cell line capabilities exemplified at 50L scale (batch process)

In demand


Multiple on-going PCL programmes (for pharma and biotech companies)

High-titre producer cell lines for any transgene


- Development of PCLs previously unachievable due to the expression of inhibitory transgenes
- Multiple LV-CAR PCLs successfully generated, including with intron-containing promoters such as EF1 α




Therapeutic LV CAR produced



Therapeutic LV produced



Cell growth profiles



Therapeutic LV CAR produced (USP yield)

■ Standard transient process
■ LentiStable™ clone for LV-CAR product

Scalable perfusion based process

- Perfusion process allows continuous harvest at higher cell densities
- Up to 14-fold titre increase compared to batch process

Available at Oxford Biomedica

- Off-the-shelf LentiStable™ packaging cell lines
- Custom LentiStable™ producer cell lines

For more information please contact:

Oxford Biomedica
+44 (0) 1865 783 000
www.oxb.com

partnering@oxb.com

